ストックスクリーナーアプリを入手
24.01
3.27%
0.76
アフターアワーズ：
24.24
0.23
+0.96%
前日終値:
$23.25
開ける：
$23.42
24時間の取引高:
4.49M
Relative Volume:
0.62
時価総額：
$2.35B
収益：
$2.48B
当期純損益:
$-57.96M
株価収益率:
-31.65
EPS:
-0.7585
ネットキャッシュフロー:
$-453.97M
1週間 パフォーマンス:
+5.26%
1か月 パフォーマンス:
+24.60%
6か月 パフォーマンス:
-61.52%
1年 パフォーマンス:
-80.94%
1日の値動き範囲:
$23.02
$24.48
1週間の範囲:
$22.79
$24.48
52週間の値動き範囲:
$10.41
$138.81
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
名前
Sarepta Therapeutics Inc
セクター
電話
617-274-4000
住所
215 FIRST STREET, CAMBRIDGE, MA
SRPT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
24.01 | 2.43B | 2.48B | -57.96M | -453.97M | -0.7585 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-22 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-29 | アップグレード | Barclays | Underweight → Equal Weight |
| 2025-07-29 | 開始されました | Bernstein | Mkt Perform |
| 2025-07-29 | 繰り返されました | H.C. Wainwright | Sell |
| 2025-07-29 | アップグレード | JP Morgan | Underweight → Neutral |
| 2025-07-29 | アップグレード | Oppenheimer | Perform → Outperform |
| 2025-07-28 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2025-07-25 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2025-07-24 | 開始されました | Citigroup | Sell |
| 2025-07-23 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2025-07-22 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2025-07-21 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2025-07-21 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-07-21 | ダウングレード | Mizuho | Outperform → Neutral |
| 2025-07-21 | ダウングレード | Needham | Hold → Underperform |
| 2025-07-21 | ダウングレード | UBS | Buy → Neutral |
| 2025-07-18 | ダウングレード | Needham | Buy → Hold |
| 2025-06-20 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2025-06-18 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-06-17 | 開始されました | Wolfe Research | Peer Perform |
| 2025-06-16 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2025-06-16 | ダウングレード | BofA Securities | Buy → Neutral |
| 2025-06-16 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2025-06-16 | ダウングレード | H.C. Wainwright | Neutral → Sell |
| 2025-06-16 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-06-16 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2025-06-06 | アップグレード | Scotiabank | Sector Perform → Sector Outperform |
| 2025-05-08 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2025-04-11 | 開始されました | Wells Fargo | Overweight |
| 2025-04-02 | アップグレード | H.C. Wainwright | Sell → Neutral |
| 2025-03-31 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | 開始されました | Deutsche Bank | Hold |
| 2024-11-27 | 繰り返されました | Needham | Buy |
| 2024-11-25 | 開始されました | H.C. Wainwright | Sell |
| 2024-11-07 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | 開始されました | Jefferies | Buy |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-07-29 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-05-31 | 開始されました | Piper Sandler | Overweight |
| 2024-05-28 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | アップグレード | Oppenheimer | Perform → Outperform |
| 2024-01-31 | 開始されました | BMO Capital Markets | Outperform |
| 2023-12-13 | 再開されました | Citigroup | Buy |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-11-21 | 開始されました | Wedbush | Outperform |
| 2023-10-31 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2023-06-23 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2023-04-26 | 開始されました | SMBC Nikko | Outperform |
| 2023-04-04 | 開始されました | Citigroup | Buy |
| 2023-03-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | 繰り返されました | BTIG Research | Buy |
| 2022-12-16 | アップグレード | UBS | Neutral → Buy |
| 2022-04-04 | 再開されました | Cantor Fitzgerald | Overweight |
| 2022-01-05 | 繰り返されました | Needham | Buy |
| 2021-12-09 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-11-05 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-09-15 | アップグレード | Guggenheim | Neutral → Buy |
| 2021-08-05 | アップグレード | JP Morgan | Underweight → Neutral |
| 2021-06-15 | 開始されました | BTIG Research | Buy |
| 2021-04-26 | 再開されました | Credit Suisse | Neutral |
| 2021-01-12 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-01-11 | ダウングレード | UBS | Buy → Neutral |
| 2021-01-08 | ダウングレード | JP Morgan | Overweight → Underweight |
| 2021-01-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | 開始されました | Berenberg | Hold |
| 2020-10-28 | 開始されました | UBS | Buy |
| 2020-08-25 | 開始されました | Raymond James | Outperform |
| 2020-08-20 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | 開始されました | Mizuho | Buy |
| 2019-11-01 | 開始されました | Guggenheim | Buy |
| 2019-08-21 | 繰り返されました | Needham | Buy |
| 2019-07-09 | 繰り返されました | Morgan Stanley | Overweight |
| 2019-07-01 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2019-03-11 | 繰り返されました | Credit Suisse | Outperform |
| 2018-10-12 | 開始されました | Bernstein | Outperform |
| 2018-10-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-09-26 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2018-09-14 | 再開されました | BofA/Merrill | Buy |
| 2018-09-06 | 開始されました | Credit Suisse | Outperform |
| 2018-08-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | 繰り返されました | Robert W. Baird | Outperform |
| 2018-06-20 | 繰り返されました | Needham | Buy |
| 2018-06-19 | 繰り返されました | H.C. Wainwright | Buy |
すべてを表示
Sarepta Therapeutics Inc (SRPT) 最新ニュース
Relative strength of Sarepta Therapeutics Inc. in sector analysisJuly 2025 Big Picture & Technical Buy Zone Confirmations - newser.com
Is Sarepta Therapeutics Inc. trending in predictive chart models2025 Market Trends & Growth Focused Stock Pick Reports - newser.com
How Sarepta Therapeutics Inc. (AB3A) stock expands through international marketsShare Buyback & Free Reliable Trade Execution Plans - newser.com
Analyzing drawdowns of Sarepta Therapeutics Inc. with statistical tools2025 Investor Takeaways & Stock Portfolio Risk Management - newser.com
Combining machine learning predictions for Sarepta Therapeutics Inc.Earnings Risk Report & Advanced Technical Signal Analysis - newser.com
Is Sarepta Therapeutics Inc. (AB3A) stock testing key supportJuly 2025 Spike Watch & Growth Focused Investment Plans - newser.com
What technical charts say about Sarepta Therapeutics Inc. stock2025 Year in Review & Verified Stock Trade Ideas - newser.com
What market sentiment indicators show for Sarepta Therapeutics Inc. (AB3A) stockJuly 2025 PostEarnings & Free Real-Time Volume Trigger Notifications - newser.com
When is the best time to exit Sarepta Therapeutics Inc.Quarterly Portfolio Review & Reliable Intraday Trade Plans - newser.com
SAREPTA THERAPEUTICS Earnings Preview: Recent $SRPT Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Can Sarepta Therapeutics Inc. (AB3A) stock attract analyst upgradesQuarterly Portfolio Review & Free Safe Entry Trade Signal Reports - newser.com
Is Sarepta Therapeutics Inc. stock supported by strong cash flows2025 Big Picture & Advanced Swing Trade Entry Plans - newser.com
What makes Sarepta Therapeutics Inc. (AB3A) stock appealing to growth investorsBear Alert & Weekly High Potential Stock Alerts - newser.com
Sarepta Therapeutics (NASDAQ:SRPT) Price Target Raised to $16.00 - MarketBeat
Is Sarepta Therapeutics Inc. stock attractive for passive investors2025 Buyback Activity & Daily Profit Maximizing Trade Tips - newser.com
What to do if you’re stuck in Sarepta Therapeutics Inc.Volume Spike & Free Risk Controlled Daily Trade Plans - newser.com
Is Sarepta Therapeutics Inc. stock ready for a breakoutJuly 2025 Trends & Weekly Setup with ROI Potential - newser.com
Is Sarepta Therapeutics Inc. stock a good choice for value investors2025 Support & Resistance & Reliable Breakout Forecasts - newser.com
How Sarepta Therapeutics Inc. stock benefits from global expansion2025 Major Catalysts & AI Powered Buy/Sell Recommendations - newser.com
Will Sarepta Therapeutics Inc. stock benefit from sector rotationJuly 2025 PreEarnings & Reliable Intraday Trade Alerts - newser.com
Sarepta Therapeutics’ Long-term Study on SRP-9001: A Boost for Investor Confidence? - TipRanks
Will breakout in Sarepta Therapeutics Inc. lead to full recoveryWeekly Risk Report & Community Consensus Trade Signals - newser.com
How to escape a deep drawdown in Sarepta Therapeutics Inc.2025 Winners & Losers & AI Driven Stock Reports - newser.com
Sarepta’s Gene Therapy Study: A Potential Game-Changer for Duchenne Muscular Dystrophy - TipRanks
Piper Sandler Maintains Sarepta Therapeutics (SRPT) Neutral Recommendation - Nasdaq
Interesting SRPT Put And Call Options For December 19th - Nasdaq
Piper Sandler Maintains Neutral Rating on SRPT, Raises Price Tar - GuruFocus
Sarepta Therapeutics (SRPT) to Release Quarterly Earnings on Monday - MarketBeat
Allianz Asset Management GmbH Has $252,000 Stock Holdings in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Can Sarepta Therapeutics Inc. stock deliver strong Q4 earningsQuarterly Market Summary & Real-Time Buy Zone Alerts - fcp.pa.gov.br
Will Sarepta Therapeutics Inc. stock keep outperforming rivalsJuly 2025 Technicals & Free Weekly Watchlist of Top Performers - fcp.pa.gov.br
Using Bollinger Bands to evaluate Sarepta Therapeutics Inc.Quarterly Portfolio Review & Entry Point Confirmation Signals - newser.com
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Rating of "Hold" by Analysts - MarketBeat
Sarepta Therapeutics to Announce Third Quarter 2025 Financial Results - BioSpace
Is Sarepta Therapeutics Inc. stock trading near support levels2025 Market Trends & Free Expert Verified Stock Movement Alerts - fcp.pa.gov.br
Sarepta’s Gene Therapy Study for Young DMD Patients: A Market Game-Changer? - TipRanks
Sarepta Therapeutics Inc (SRPT) 財務データ
収益
当期純利益
現金流量
EPS
1.62%
0.21%
大文字化:
|
ボリューム (24 時間):